Case 22-2009: A 59-year-old man with skin and pulmonary lesions after bone marrow transplantation

New England Journal of Medicine

Volumn 361, Issue 3, 2009, Pages 287-

  Patterson, Thomas F ^a,b   Mackool, Bonnie T ^c   Gilman, Matthew D ^c   Piris, Adriano ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ATOVAQUONE; AZACITIDINE; CEFEPIME; CONTRAST MEDIUM; CYTARABINE; FAMCICLOVIR; FLUCONAZOLE; IDARUBICIN; INTERFERON; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; OMEPRAZOLE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; VANCOMYCIN; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANAMNESIS; APPENDICITIS; ARTICLE; BLOOD CULTURE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DEPRESSION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEVER; FUSARIOSIS; HEEL PAIN; HEPATITIS C; HUMAN; HUMAN TISSUE; LUNG LESION; MALE; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; PANCYTOPENIA; PRIORITY JOURNAL; SKIN DEFECT; THROMBOCYTE TRANSFUSION; THRUSH; URINALYSIS; URINE CULTURE; BIOPSY; BONE MARROW EXAMINATION; BONE MARROW TRANSPLANTATION; CLINICAL OBSERVATION; CLINICAL STUDY; DERMATOMYCOSIS; DIAGNOSIS; DRUG ANTAGONISM; FATALITY; FUSARIUM; IMMUNE DEFICIENCY; ISOLATION AND PURIFICATION; LUNG; LUNG MYCOSIS; MIDDLE AGED; OPPORTUNISTIC INFECTION; PATHOLOGY; RADIOGRAPHY; SKIN;

ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; BIOPSY; BONE MARROW EXAMINATION; BONE MARROW TRANSPLANTATION; DERMATOMYCOSES; DIAGNOSIS, DIFFERENTIAL; DRUG ANTAGONISM; FATAL OUTCOME; FUSARIUM; HUMANS; IMMUNOCOMPROMISED HOST; LEUKEMIA, MYELOID, ACUTE; LUNG; LUNG DISEASES, FUNGAL; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; OPPORTUNISTIC INFECTIONS; SKIN;

EID: 67650905163     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcpc0809065     Document Type: Article

References (26)

1. Nucci M. Spector N, Bueno AP, et al. Risk factors and attributable mortality associated with superinfections in neutropenic patients with cancer. Clin Infect Dis 1997;24:575-9.
2. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patient with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006;91:1068-75.
3. Pagano L, Fianchi L, Leone G. Fungal pneumonia due to molds in patients with hematological malignancies. J Chemother 2006;18:339-52.
4. Gorschlüter M, Mey U, Strehl J, et al. Invasive fungal infections in neutropenic enterocolitis: a systematic analysis of pathogens, incidence, treatment and mortality in adult patients. BMC Infect Dis 2006;6: 35.
5. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357:2601-14.
6. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998;338:1741-51.
7. Mühlemann K, Wenger C, Zenhäusern R, Täuber MG. Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia 2005; 19:545-50.
8. Pagano L, Girmenia C, Mele L, et al. Infections caused by filamentous fungi in patients with hematologic malignancies: a report of 391 cases by GIMEMA Infection Program. Haematologica 2001;86:862-70.
9. Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006;91:986-9.
10. Patterson TF. Advances and challenges in management of invasive mycoses. Lancet 2005;366:1013-25.
11. Marr KA. The changing spectrum of candidemia in oncology patients: therapeutic implications. Curr Opin Infect Dis 2000;13:615-20.
12. Pappas PG. Invasive candidiasis. Infect Dis Clin North Am 2006;20:485-506.
13. Haron E, Vartivarian S, Anaissie E, Dekmezian R, Bodey GP. Primary Candi da pneumonia: experience at a large cancer center and review of the literature. Medicine (Baltimore) 1993;72:137-42.
14. Chayakulkeeree M, Perfect JR. Cryp-tococcosis. Infect Dis Clin North Am 2006;20:507-44.
15. Inhaled beclomethasone dipropionate in allergic bronchopulmonary aspergillosis: report to the Research Committee of the British Thoracic Association. Br J Dis Chest 1979;73:349-56.
16. Kauffman CA. Endemic mycoses in patients with hematologic malignancies. Semin Respir Infect 2002;17:106-12.
17. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984;100:345-51.
18. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997;175:1459-66.
19. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine (Baltimore) 2000;79:250-60.
20. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical sig nificance of the halo sign. Clin Infect Dis 2007;44:373-9.
21. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005;41:634-53.
22. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillusactive antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005;191:1350-60.
23. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007;20:695-704.
24. Nucci M, Anaissie EJ, Queiroz-Telles F, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 2003;98:315-9.
25. Mennink-Kersten MA, Verweij PE. Non-culture-based diagnostics for opportunistic fungi. Infect Dis Clin North Am 2006;20:711-27.
26. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997; 90:999-1008.